Multiple System Atrophy News
Click figure to go to SDS/MSA Website Multiple System Atrophy News - November 2002 Table of Contents 1. SUPPORT GROUP NEWS 2. MULTIPLE SYSTEM ATROPHY RESEARCH NEWS 3. CLINICAL TRIALS RECRUITING MSA PATIENTS 4. ODDS AND ENDS ______________________________________________________ 1. SUPPORT GROUP NEWS a. Boston Meeting Audio Tapes Now Available Audio tapes of the Boston SDS/MSA Support Group meeting held in May 2002 are
now available. The set consists of two audio cassettes with one hour of recording on each
side. (Four hours total listening time). A contribution of at least $20.00 is
requested to help cover the cost of production and delivery of these tapes. To receive a set, please mail a check to: Don't forget to include your name and mailing address with your check. Don Summers will mail your set of tapes as soon as possible after your
donation is received. They will be sent First Class Mail to ensure quick
delivery. Don says, "I have listened to the whole set and am very pleased with the
sound reproduction. The physician's presentations are very good as is the
recording of the patients and caregivers questions and answers. I'm looking
forward to sending these out. Hope to hear from you soon!" ______________________________________________________ 2. MULTIPLE SYSTEM ATROPHY RESEARCH NEWS a. Researchers Meet to Test MSA Rating Scale "My wife signed up for Dr. Shults' study as soon as we heard about it, and we
have spoken with him a number of times. We're lucky to have him so interested in
the disease. My wife was one of eight who were asked to go to the Parkinson's Institute in
Sunnyvale 2 or 3 months ago to be examined by Dr. Shults and 6 other US and
foreign neurologists who are involved in the study. It was a very formidable
group, including Sid Gilman from Michigan, Stephen Reich from Johns Hopkins,
Paola Sandroni from the Mayo Clinic, Fred Marshall from the University of
Rochester in NY, Caroline Tanner from the Sunnyvale Parkinson's Institute, and
Gregor Wenning from Austria. We were told that Dr. Wenning is the one who
essentially created the MSA rating scale that was being tested during my wife's
visit. The purpose of seeing these 8 people with MSA was to test the draft of the
MSA rating scale and to agree on the protocol they were all going to use in the
study to determine whether or not the individuals they were going to study did
or did not have MSA, and how to describe their symptoms, and the degree of
development of each symptom. In essence they were trying to reach agreement on a
common vocabulary, common standards, common procedures, common objectives, and
common collection of data and information. They examined each of the 8 separately, for about 2 hours each. All 7 of the
doctors hovered over my wife at the same time as they put her through many of
the tests which neurologists do for these diseases (i.e., look up, look down,
follow my finger, touch my finger, touch your nose, stand up, walk, turn
quickly, etc. etc.). They asked her many questions. They televised the whole
thing. One interesting thing was that several of the doctors suggested that she
didn't have any cerebellar involvement, and that what she had was more PSP than
MSA. The others didn't agree. Several days later, we had our regular every-two month visit with my wife's
neurologist, Dr. Dan Geschwind at UCLA. We got Dr. Shults to call Dr. Geschwind
and share the observations the examining doctors had on my wife. Dr. Geschwind
has no doubt that my wife predominantly has MSA. Dr. Shults passed on a
suggestion from one of the doctors that she should try Klonopin to ease her
rigidity. Although she tried it and it didn't help, it was particularly
considerate of Dr. Shults to pass all this information on to Dr. Geschwind." ______________________________________________________ 3. CLINICAL TRIALS RECRUITING MSA PATIENTS a. Intravenous Immunoglobulin Therapy In Patients With Cerebellar
Degeneration The Efficacy of High-Dose Intravenous Immunoglobulin Therapy In Patients With
Cerebellar Degeneration: A Double Blind, Placebo Controlled Trial
http://clinicalstudies.info.nih.gov/detail/A_2002-N-0185.html Summary: This study will examine whether high-dose intravenous immunoglobulin
(IVIG) is safe and effective for treating cerebellar ataxia-degeneration of the
cerebellum, the part of the brain responsible for coordinating muscle movements
and balance. The disease causes a slowly progressive impairment of speech and
balance, with patients often developing slurred speech, tremor, clumsiness of
the hands, and walking difficulties (ataxia). IVIG is derived from donated blood
that has been purified, cleaned and processed into a form that can be infused.
IVIG is an immune suppressant that is routinely used to treat other neurological
conditions. INCLUSION CRITERIA: Adults over 18 with hereditary or sporadic cerebellar degeneration. Sporadic
cerebellar degeneration may include the cerebellar predominant variant of
Multiple System Atrophy (MSA-C). Contacts: Full details of this trial can be found at:
http://clinicalstudies.info.nih.gov/detail/A_2002-N-0185.html ______________________________________________________ 4. ODDS & ENDS a. MSA Researcher, inducted to the American Academy of Arts and Sciences Dr. Sid Gilman, Ataxia & MSA Researcher, was inducted to the American Academy
of Arts and Sciences in 2001. --------------------------------
http://www.amacad.org/members/2001alpha.htm#G Sid Gilman, II:5 Professor and Chair, Department of Neurology University of Michigan Director, Michigan Alzheimer's Disease Research Center. Biochemical changes
in neurodegenerative diseases studied with positron emission tomography.
Discovered the cerebral disorders resulting from open heart operations.
Demonstrated generalized cerebral glucose hypermetabolism in Friedreich's
ataxia, focal cerebral hypometabolism in chronic alcoholism,
olivopontocerebellar atrophy and multiple system atrophy, and preservation of
benzodiazepine receptors in these disorders. --------------------------------
http://www.amacad.org/news/2001induct.htm American Academy Inducted 2001 Fellows October 13, 2001- On October 13th, the American Academy of Arts and Sciences
welcomed new Fellows from across the nation and around the world. In an
Induction ceremony held in Cambridge, Academy officers led by President Patricia
Meyer Spacks (University of Virginia) greeted the new Fellows-a diverse class of
scholars, scientists, public officials, artists, and business leaders who bring
expertise in areas ranging from photography to the study of diabetes.
http://www.amacad.org/index.htm Founded in 1780, the American Academy of Arts and Sciences is an
international learned society composed of the world's leading scientists,
scholars, artists, business people, and public leaders. With a current
membership of 3,700 American Fellows and 600 Foreign Honorary Members, the
Academy has four major goals: - Promoting service and study through analysis of critical social and
intellectual issues and the development of practical policy alternatives; - Fostering public engagement and the exchange of ideas with meetings,
conferences, and symposia bringing diverse perspectives to the examination of
issues of common concern; - Mentoring a new generation of scholars and thinkers through the newly
established Visiting Scholars Program; - Honoring excellence by electing to membership men and women in a broad
range of disciplines and professions. The Academy's main headquarters are in Cambridge, Massachusetts. With its
geographically diverse membership, it has also established regional centers at
the University of Chicago and at the University of California, Irvine, and
conducts activities in this country and abroad. If you are interested in being a support group leader or local contact send a
note to MSA-Contacts-owner@yahoogroups.com ______________________________________________________________________ To subscribe to the MSA Online Support Group Please visit http://groups.yahoo.com/group/shydrager ______________________________________________________________________
a. Boston Meeting Audio Tapes Now Available
a. Researchers Meet to Test MSA Rating Scale
a. Intravenous Immunoglobulin Therapy In Patients With
Cerebellar Degeneration
a. MSA Researcher inducted to the American Academy of Arts
and Sciences
The SDS/MSA Support Group
P.O. Box 279
Coupland, TX 78615
Posted with permission from Robert Gelber
Patient Recruitment and Public Liaison Office
Building 61
10 Cloister Court
Bethesda, Maryland 20892-4754
Toll Free: 1-800-411-1222
TTY: 301-594-9774 (local),1-866-411-1010 (toll free)
Fax: 301-480-9793
Electronic Mail:prpl@mail.cc.nih.gov